NASDAQ · COCHW

Envoy Medical, Inc.

$0.04 +$0.01 (+20.65%) 1D Market open

Key Metrics

$2.60M
Market cap
4.02×
P/E · TTM
−$7.00K
Revenue · TTM
$647.00K
Net income
EPS · TTM $0.01
Dividend yield
Free cash flow
Beta · 1Y 2.18
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 14
    From its Mar 16 high, the share price fell 65%.

    Peak close $0.09 on Mar 16; trough close $0.03 on Jul 14. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -65%
  • Mar 16
    The stock moved +55.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 16
  • Feb 11
    The stock moved +66.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 11

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.02 – $0.14
Avg volume · 20D40.2K
Net cash
Book value / share$0.15
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNASDAQ
About Envoy Medical, Inc.
IPO dateOct 2, 2023
Employees47

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E4.02
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №$0.18

Profitability

Gross
Operating 12,171.4%
Net -9,242.9%
FCF
ROE / ROIC -14.9% · —

Financial Health

Current ratio2.27
Quick ratio2.14
Debt / equity
Debt / EBITDA
Net cash
Working capital$15.47M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-14.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$0.18 vs $0.04
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings